PHANTOM PLUS CERAMIC CAGE SYSTEM
Device Facts
| Record ID | K121892 |
|---|---|
| Device Name | PHANTOM PLUS CERAMIC CAGE SYSTEM |
| Applicant | Amedica Corp. |
| Product Code | MAX · Orthopedic |
| Decision Date | Aug 24, 2012 |
| Decision | SESE |
| Submission Type | Special |
| Regulation | 21 CFR 888.3080 |
| Device Class | Class 2 |
| Attributes | Therapeutic |
Indications for Use
The Phantom Plus Ceramic Cages-Lumbar are intervertebral body fusion devices indicated for use with autogenous bone graft in patients with degenerative disc disease (DDD) at one level or two contiguous levels from L2 to S1. DDD is defined as back pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies. The DDD patients may also have up to Grade I spondylolisthesis at the involved level(s). These patients should be skeletally mature and have six (6) months of nonoperative therapy. The Phantom Plus Ceramic Cage System-Lumbar is to be filled with autogenous bone graft material. The Phantom Plus Ceramic Cages-Lumbar are intended to be used with supplemental spinal fixation systems, such as Preference Pedicle Screw System. The Phantom Plus Ceramic Cages-Cervical are indicated for use in skeletally mature patients with degenerative disc disease (DDD) of the cervical spine with accompanying radicular symptoms at one disc level. DDD is defined as discogenic pain with degeneration of the disc confirmed by patient history and radiographic studies. Phantom Plus Ceramic Cages-Cervical are used to facilitate intervertebral body fusion in the cervical spine and are placed via an anterior approach at the C3 to C7 disc levels using autograft bone. The Phantom Plus Ceramic Cages-Cervical are to used with supplemental fixation. Patients should have at least six (6) months of non-operative treatment with an intervertebral cage.
Device Story
Phantom Plus Ceramic Cage System consists of hollow, convex, bullet-nosed vertebral body spacers with an axial void for autogenous bone graft. Implants feature angular teeth for endplate grip and expulsion resistance. Available in various lengths (14-45mm) and heights (6-22mm). Used by surgeons in spinal fusion procedures to facilitate intervertebral stabilization. Requires supplemental spinal fixation systems. Benefits include structural support for fusion in DDD patients.
Clinical Evidence
No clinical data. Substantial equivalence supported by bench testing and engineering analyses, including adherence to ASTM F2077, ASTM F1839, ASTM F1877, ASTM F04.25.02.02, and AAMI TIR 33 standards.
Technological Characteristics
Ceramic intervertebral body fusion device. Features hollow design with axial void for bone graft and angular teeth for fixation. Dimensions: 6-22mm height, 14-45mm length. Standards: ASTM F2077, ASTM F1839, ASTM F1877, ASTM F04.25.02.02, AAMI TIR 33.
Indications for Use
Indicated for skeletally mature patients with degenerative disc disease (DDD) requiring intervertebral body fusion. Lumbar: L2-S1 (1-2 levels), may include Grade I spondylolisthesis, requires 6 months non-operative therapy. Cervical: C3-C7 (1 level) with radicular symptoms, requires 6 months non-operative therapy. Must be used with autogenous bone graft and supplemental spinal fixation.
Regulatory Classification
Identification
An intervertebral body fusion device is an implanted single or multiple component spinal device made from a variety of materials, including titanium and polymers. The device is inserted into the intervertebral body space of the cervical or lumbosacral spine, and is intended for intervertebral body fusion.
Special Controls
*Classification.* (1) Class II (special controls) for intervertebral body fusion devices that contain bone grafting material. The special control is the FDA guidance document entitled “Class II Special Controls Guidance Document: Intervertebral Body Fusion Device.” See § 888.1(e) for the availability of this guidance document.(2) Class III (premarket approval) for intervertebral body fusion devices that include any therapeutic biologic (e.g., bone morphogenic protein). Intervertebral body fusion devices that contain any therapeutic biologic require premarket approval. (c) *Date premarket approval application (PMA) or notice of product development protocol (PDP) is required.* Devices described in paragraph (b)(2) of this section shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.